Autolus Therapeutics (NASDAQ:AUTL) Sees Unusually-High Trading Volume – Time to Buy?

Autolus Therapeutics plc (NASDAQ:AUTL) shares saw unusually-strong trading volume on Wednesday . Approximately 2,674,034 shares traded hands during trading, an increase of 93% from the previous session’s volume of 1,386,659 shares.The stock last traded at $3.42 and had previously closed at $3.38.

Autolus Therapeutics Stock Performance

The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average price is $3.99 and its two-hundred day moving average price is $4.02. The stock has a market capitalization of $949.96 million, a PE ratio of -2.91 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, equities research analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AUTL. Avoro Capital Advisors LLC purchased a new position in shares of Autolus Therapeutics in the first quarter valued at approximately $78,765,000. Price T Rowe Associates Inc. MD boosted its stake in Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after purchasing an additional 2,487,778 shares during the last quarter. Great Point Partners LLC grew its holdings in shares of Autolus Therapeutics by 195.0% during the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after buying an additional 2,275,000 shares in the last quarter. Affinity Asset Advisors LLC raised its position in shares of Autolus Therapeutics by 117.7% in the first quarter. Affinity Asset Advisors LLC now owns 3,375,000 shares of the company’s stock valued at $21,532,000 after buying an additional 1,824,592 shares during the last quarter. Finally, Armistice Capital LLC lifted its stake in shares of Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after buying an additional 1,578,000 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.